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Genome editing is the process of precisely modifying
the nucleotide sequence of the genome. It has
provided a powerful approach to research questions
but, with the development of a new set of tools, it is
now possible to achieve frequencies of genome
editing that are high enough to be useful
therapeutically. Genome editing is being developed to
treat not only monogenic diseases but also infectious
diseases and diseases that have both a genetic and an
environmental component.modify their course.The potential therapeutic importance of genome
editing
In 1901, Sir Archibald Garrod identified alkaptonuria as
the first known human genetic disease. Today, we
recognize that there are at least 8000 human diseases that
are caused by mutations in single genes (monogenic dis-
eases); the number increases almost every day [1, 2].
While all of these diseases are classified as ‘rare’ in the US
because they affect fewer than 200,000 people, they may
affect over 400 million people worldwide. Some, such as
sickle cell disease, affect tens of millions of people around
the world and are only ‘rare’ in certain parts of the world,
including the US, Europe and far east Asia. For a tiny sub-
set of patients, allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT) or solid organ transplantation can
be used to cure their genetic disease, but for the vast ma-
jority of patients there is no cure and at best they are
treated by management of symptoms.
Therapeutic genome editing was born out of the idea
that the ideal therapy for monogenic diseases would be
to develop a method that can correct the disease-
causing mutations directly; but as genome editing has
developed in concert with continuing improvements inCorrespondence: mporteus@stanford.edu
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monogenic diseases, the principle of genome editing is
being developed not only to cure monogenic diseases
but also to cure more common diseases that have multi-
factorial origins. The use of genome editing to cure
monogenic disease is conceptually simple (genome edit-
ing can be used to correct the underlying genomic typo-
graphical errors), but the power of genome editing is
that it provides a mechanism that can do more than
simply modify single nucleotides. It is a method that can
make more sophisticated and nuanced genomic changes,
which can be used to cure more common diseases or to
The exact nature of the therapeutic edit has to be
driven by a solid understanding of the interplay between
the underlying genetics and the specific pathophysiology
of the disease. That is, one editing strategy might be ap-
propriate for one disease but not applicable to another.
This review will describe the basic strategies of genome
editing and the tools that are now available both to cor-
rect typographical errors and to make more sophisti-
cated changes to the genome. I will then discuss how
genome editing is being developed to treat genetic, in-
fectious, and acquired diseases. Finally, I end with a brief
discussion of issues surrounding the use of genome edit-
ing in situations that might cause the engineered genetic
change to be passed from one generation to the next.The development of genome editing and the
contemporary toolbox
Genome editing, also previously known as gene target-
ing, has been a powerful research tool for scientists. In
particular, the ease of gene targeting in yeast was one
factor that made yeast such an important model organ-
ism in studies of the pathophysiology of human disease
[3, 4]. The importance of gene targeting as a research
tool was further highlighted by the awarding of the Nobel
Prize in Physiology or Medicine in 2007 to Drs Oliver
Smithies and Mario Capecchi for their development of
gene targeting in mouse embryonic stem cells and foristributed under the terms of the Creative Commons Attribution 4.0 International
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transformational advance in understanding human patho-
physiology [5, 6]. Even in the earliest days of gene therapy,
it was recognized that genome editing might be the ideal
approach for curing genetic diseases, but the earliest stud-
ies were stymied by the low absolute frequency of gene
correction by homologous recombination in human som-
atic cells (10−6) [7–9]. A critical breakthrough was the dis-
covery that by creating a site-specific DNA double-
stranded break (DSB) in the target gene it is possible to
stimulate genome editing by homologous recombination
by 2–5 orders of magnitude, providing overall frequencies
of 5 % or more [10–13]. In addition to stimulating gene
targeting by homologous recombination by five orders of
magnitude, a site-specific DSB could stimulate mutations
such as small insertions/deletions at the site of the DSB by
nine orders of magnitude. Thus, the DSB became a key
principle in the development of genome editing.
The basic process of nuclease-based genome editing is
to create a specific DSB in the genome and then allow
the cell’s own endogenous repair machinery to repair the
break (Fig. 1). The cell can repair the break using one of
two basic mechanisms: nonhomologous end-joining
(NHEJ) or homologous recombination (HR) (see Box 1;
Fig. 1) [14–17]. When the editing of a single break oc-
curs by NHEJ, insertions/deletions are created at the site
of the break [17] (Fig. 1a). The size of deletions tends to
be larger than that of insertions, except when extrachro-
mosomal DNA is captured at the site of the break (a rare
but measurable occurrence), in which case insertions of
hundreds of basepairs (bp) can occur [18, 19]. When
editing of a single break occurs by HR using a provided
donor sequence, precise nucleotide changes in the gen-
ome range from a single base insertion to the introduc-
tion of large cassette of genes (Fig. 1c) [20, 21]. When
the editing of two breaks occurs by NHEJ, chromosomal
deletions, inversions or translocations can be created
(Fig. 1b) [22]. These gross chromosomal rearrangements
can be generated intentionally for therapeutic purposes,
but they also must be evaluated because any nuclease
platform has the potential to produce off-target effects.
In seminal studies of the importance of DSBs, re-
searchers used an artificial system in which the target site
for a natural homing endonuclease (also sometimes called
a ‘meganuclease’), I-SceI, was engineered into the genome
of somatic cells; the frequency of genome editing was mea-
sured at that engineered I-SceI site [9, 13, 23–25]. The bar-
rier to high-frequency editing was that neither I-SceI nor
the other meganucleases could be easily re-engineered to
recognize natural target sites in the genome. The first so-
lution to this problem was the development of zinc-finger
nucleases (ZFNs) (originally called ‘chimeric restriction en-
zymes’, then called ‘chimeric nucleases’) [26–28]. ZFNs are
artificial proteins in which a zinc-finger DNA-bindingdomain is fused to the nonspecific nuclease domain de-
rived from the FokI Type II S restriction endonuclease.
At first, engineered ZFNs were shown to be as efficient
as I-SceI in stimulating gene targeting in human somatic
cells. Then, because the zinc-finger DNA binding do-
main can be engineered to recognize new target sites,
ZFN-based protocols became the first method used to
stimulate genome editing in human somatic cells to fre-
quencies that are therapeutically relevant [9, 29, 30].
This work in human somatic cells paralleled the import-
ant work by Dana Carroll and his colleagues, who
showed that ZFNs could be used to edit the complex
genome of eukaryotic Drosophila melanogaster, both by
mutagenic NHEJ and by HR [17, 31]. For a number of
years, the only engineered nucleases in the genome
editing toolbox were ZFNs [32, 33] and re-engineered
meganucleases [34]. In the past 5 years, however, the devel-
opment of TAL effector nucleases (TALENs) [35–37],
CRISPR/Cas9 nucleases [38–40], and hybrid nuclease plat-
forms [41–43] have dramatically expanded the engineered
nuclease toolbox.
There are four basic and two hybrid engineered nucle-
ase platforms that include engineered meganucleases,
ZFNs, TALENs, CRISPR/Cas9 nucleases, mega-TAL nu-
cleases, and Cas9-FokI nucleases (Box 2; Table 1). There
are subtle differences between each of these nuclease
platforms—for example, the type of break that is created
is different: meganucleases and mega-TALs generate
breaks with 3′ overhangs; ZFNs create breaks with 5′
overhangs; TALENs create breaks that are variable in
position that are usually (but not always) 5′ overhangs,
as determined by the properties of the FokI nuclease
(Fn); and CRISPR/Cas9 nucleases create blunt breaks. In
general, however, each of these platforms mediates their
editing effects through the creation of a DSB and thus
they share a fundamental mechanism of action.
The only tool needed for NHEJ-mediated genome edit-
ing is an engineered nuclease, but HR-mediated genome
editing also requires an engineered donor vector. Donor
vectors can be designed to template single bp changes or
to insert large multi-gene cassettes into the genome.
The homology arms for nuclease-mediated genome edit-
ing can be much shorter than those required for HR-
mediated gene targeting in murine embryonic stem cells:
instead of having to be 10 kilobases or greater, they can
be as short as 400 bp [18]. Shortening the homology
arms to below 400 bp does, however, seem to decrease
the overall editing efficiency. Single-stranded oligonucle-
otides (ssODNs) have also been used to template small
nucleotide changes after the induction of a DSB [44].
The ease with which ssODNs can be synthesized makes
this approach relatively accessible to the researcher, but
the mechanism by which ssODNs create a targeted
change in the genome does not rely on the classic HR
Fig. 1 Nuclease-based genome editing creates a specific double-stranded break (DSB) in the genome and then allows the cell’s own endogenous
repair machinery to repair the break. a When the editing of a single break occurs by nonhomologous end-joining (NHEJ), insertions/deletions are
created at the site of the break. b When the editing of two DSBs occurs by NHEJ, chromosomal deletions, inversions or translocations can be created.
c When editing of a single DSB occurs by homologous recombination (HR) using a provided donor sequence, precise changes in the nucleotide
sequence ranging from a single base insertion to the introduction of a large cassette of genes can occur. Using NHEJ and HR mediated editing, it is
now possible to inactivate genetic elements, create defined deletions ranging from a few bases to thousands of bases, and precise nucleotide changes
to the sequence of the genome. AAV Adeno-associated virus, bps Basepairs, IDLV Integrase-deficient lentivirus
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induce a replication and cell cycle arrest even in cancer
cell lines [45] and would probably be even more problem-
atic in primary therapeutically relevant human cell types,
as demonstrated in part by the work of Hoban et al. [46].
Issues of delivery and process development
A mantra in the field has been that the three most im-
portant issues in gene therapy are delivery, delivery, anddelivery. As the toolbox for genome editing has ex-
panded, that mantra now also applies in many respects
to therapeutic genome editing: what is the optimal
process to deliver highly active genome-editing reagents
into the most clinically relevant cell type? The answer to
this question is increasingly disease specific. An import-
ant consideration in determining an appropriate delivery
strategy is that genome editing, in contrast to gene-
augmentation strategies, is a hit and run approach. In
Box 1. The mechanism of DNA double-strand break repair
The cell has two primary double-strand break (DSB) repair mechanisms: nonhomologous end-joining (NHEJ) and homologous recombination
(HR) [15, 102, 103] (Fig. 1). In NHEJ, the two ends of the broken DNA are ligated back together (by a ‘stitching’ mechanism). For DSBs
that are generated by an engineered nuclease, the NHEJ process has high fidelity with >70 % of the breaks being joined in a precise
and nonmutagenic fashion [104, 105]. If the nuclease is still active after rejoining, the nuclease will recut the site, creating another DSB
and eventually leading to an insertion/deletion at the site of the break. The size of the insertion/deletion is usually 1–15 basepairs but
can be much larger; insertions often incorporate random pieces of DNA that are present in the nucleus [18, 19]. Thus, genome editing
by NHEJ whereby mutations are created at specific sites in the genome is an iterative process of break and repair until the target site
can no longer be cut by the engineered nuclease.
If two DSBs are created simultaneously on the same chromosome, then the NHEJ machinery will create a deletion between the two
sites [22]. The use of two DSBs can increase the frequency of inactivating a genetic element [104] or can be used to delete large
genomic regions for therapeutic purposes [57]. When the frequency of a deletion is about 1 %, two simultaneous DSBs will result in the
inversion of the sequence intervening between the two DSBs. If two DSBs are simultaneously created on different chromosomes, then
chromosomal translocations can be created [106, 107]. Such induced chromosomal translocations are useful as a research tool and must
be considered when evaluating the safety of a therapeutic genome-editing strategy.
In HR, the cell identifies a piece of DNA that has homology to the site of the DSB and then uses that homologous undamaged DNA as
a template in a ‘copy and paste’ mechanism. The template DNA for HR is usually the undamaged sister chromatid. Rarely, the template
is the undamaged chromosomal homolog (leading to loss of heterozygosity). In genome editing, the template is an introduced piece of
DNA, called a ‘donor’. The donor can be engineered such that when it is used as a template by the HR machinery, single nucleotide
changes or multikilobase nucleotide changes are introduced into the genome. In summary, genome editing by NHEJ results in a
mutation that has a spatially precise genomic location, whereas genome editing by HR results in a genomic change whose location and
nucleotide sequence can both be specified.
The frequencies of NHEJ- and HR-mediated genome editing vary from experimental system to experimental system. In general,
NHEJ-mediated editing is more frequent than HR-mediated editing, but when HR-mediated editing is optimized, its frequency can
exceed that of NHEJ-mediated editing, even without the use of small molecules [18]. In addition, the relative frequencies of NHEJ-
and HR-mediated editing can be altered by small molecules or by RNAi which in some cases work by inhibiting the canonical NHEJ
pathway but in other cases through a mechanism that is not well understood, but that these perturbations might result in increased
off-target genomic instability and may not be therapeutically useful [108].
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needed but should be avoided: continued expression of a
nuclease increases the probability of deleterious genomic
instability and may either compromise the edited cell’s
fitness or predispose the exposed cell to transformation.
For ex vivo manipulation of cells, standard nonviral
delivery of the nuclease as RNA, or ribonucleoprotein
(RNP) for the CRISPR/Cas9 system, seems to be the
most promising approach. Delivering the nuclease com-
ponent as RNA or RNP ensures that both the activation
of the Type I interferon response and the duration of the
expression are minimized. The RNA or RNP can be deliv-
ered into a cell by a variety of mechanisms that are deter-
mined by the specific cell type’s ability to be transfected
with different complexes. A universal method of delivery
that is effective across all cell types is electroporation, in
which cells are mixed with the RNA or RNP and a brief
electrical pulse is passed through the mixture, thereby cre-
ating membrane holes through which the RNP or RNA
enters. Multiple different electroporation devices are nowavailable and, amazingly, electroporation conditions can
be found that create minimal cellular toxicity as long as
DNA or other nucleic acids that activate the innate im-
mune system are not included in the mixture. For applica-
tions that simply require the delivery of the nuclease, this
seems to be a robust solution. For applications that re-
quire HR-mediated editing, a DNA molecule also needs to
be delivered. Delivery of naked DNA into cancer cell lines
has been an effective method to deliver the donor vector,
but the delivery of naked DNA into primary cells, particu-
larly T cells and hematopoietic stem and progenitor cells,
activates a deleterious innate immune response that both
decreases the frequency of genome editing and compro-
mises the fitness of the edited cell. Using adeno-associated
virus (AAV) to deliver the donor template into cells may
be a solution to this problem because AAV, like many vi-
ruses, has evolved to escape recognition by the innate
intracellular immune response [47–50].
For therapeutic applications that require in vivo edit-
ing of cells, the challenge is greater and a solution has
Box 2. Engineered nuclease platforms
Engineered meganucleases are derived from the large family of natural homing endonucleases (hundreds of members) [109]. A small
number of these endonucleases have been designed to recognize natural target sites in the genome using a variety of strategies,
including structure-based design and yeast surface display [34, 110]. Natural meganucleases have historically been the gold standard for
specificity, but the challenge of engineering meganucleases for novel target sites has limited their translational development. Furthermore,
the specificity of engineered meganucleases has not been fully evaluated.
Zinc-finger nucleases (ZFNs) are artificial proteins in which a zinc-finger DNA-binding domain is fused to the nonspecific nuclease domain
from FokI [28, 33]. As the nuclease domain needs to dimerize in order to cut DNA efficiently, a pair of ZFNs needs to be engineered for each
target site and these must be oriented correctly to allow dimerization. Zinc-finger-DNA binding domains can be engineered for novel target
sites using a variety of strategies, including phage display, modular assembly, bacteria-based two-hybrid and one-hybrid systems, and
combination approaches [32]. Engineering ZFNs that have high activity and high specificity to endogenous target sites remains
challenging, although ZFN design strategies are continually improving. The best-quality ZFNs have been made by Sangamo using a
combination of phage display and modular display first developed by Klug and his co-workers [111] followed by rational design. These
ZFNs have entered clinical trials in which the engineered T cells have been shown to be safe [65].
TAL effector nucleases (TALENs) are also artificial proteins. They share a similar structure to ZFNs in which an engineered DNA-binding
domain is fused to the nuclease domain from FokI [36]. In TALENs, the DNA-binding domain is engineered by assembling a series of TAL
repeats, with each repeat mediating interaction with a single base through a two-amino acid repeat variable di-residue (RVD) that can
be described by a simple code [112, 113]. Thus, creating a highly active TALEN is much simpler than creating a highly active ZFN and
simply involves using the code to assemble the correct TAL repeats needed to recognize a novel target sequence. In addition to the
TAL repeats using natural RVDs, TAL repeats using engineered RVDs are now being used to create a TALEN [91]. These engineered RVDs
might have increased specificity over natural RVDs, although that remains to be further studied. As for ZFNs, a pair of TALENs needs to
be engineered to recognize a single target site. Even TALENs that use TAL repeats containing natural RVDs may have better specificity
than ZFNs.
CRISPR/Cas9 nucleases (unfortunately, there is no agreement on a shorter abbreviation as CRISPR is already an abbreviation of
‘Clustered Regularly Interspaced Short Palindromic Repeats’) are derived from a bacteria-based adaptive immune system [114, 115]. In
contrast to the other three platforms, the CRISPR/Cas9 nuclease system does not derive specificity through protein–DNA interaction but
instead through RNA–DNA Watson-Crick base pairing. In the CRISPR/Cas9 system, a single-guide RNA (sgRNA) is designed such that the
20-bp recognition region of the sgRNA is identical to the desired target site (for Cas9, this 20-bp sequence is derived from Streptococcus
pyogenes). The target site must be adjacent to a proto-spacer adjacent motif (PAM) sequence, which the Cas9 protein uses to identify
target sites [115]. The multifunctional Cas9 protein, in complex with the sgRNA, is able to unwind double-stranded DNA, to interrogate
whether the guide strand is sufficiently identical to the target site (small mismatches and bulges are tolerated [92, 116–119]) and then to
create a blunt DSB if there is sufficient identity. Thus, CRISPR/Cas9 nucleases can be engineered very easily and between a third and a
half of designed nucleases seem to be active at their desired target site.
In addition to the four basic platforms described above, other nucleases have been engineered to recognize therapeutically relevant
human target sites. In Mega-TALs, a re-engineered meganuclease is fused to a small number of TAL effector repeats in order to increase
binding affinity [41, 49]. In Cas9-Fn fusions, a nuclease inactive Cas9 protein is fused to the FokI nuclease (Fn) domain [42, 43, 93]. Like
ZFNs and TALENs, the Cas9-Fn platform requires a pair of nucleases to be engineered to cut a specific target site. Finally, the proof-of-
concept work of Roth and co-workers [120] showed that nickases could stimulate gene targeting, and so nickase versions of the nuclease
platforms have been studied. The nickase versions may have improved specificity because they are associated with a decreased probability of
generating an insertion/deletion at an off-target site, but they are usually 10-fold or more less active in stimulating HR-mediated genome
editing at the on-target site. Thus, nickase versions may not have sufficient on-target editing activity to be therapeutically viable. The
size of the relevant transcripts is an important consideration in determining the ease with which the platform might be packaged into
various delivery platforms. For example, recombinant adeno-associated virus (AAV) has a packaging limit of 4.7 kilobases which is too
small to package a pair of TALENs or the Cas9 cDNA of S. pyogenes, but not of Staphylococcus aureus [70].
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Table 1 Contrasting characteristics of the four standard nuclease platforms
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delivery problem may differ depending on which target
cell type needs to be identified. The solution for editing
hepatocytes, for example, will probably be different than
that for editing muscle, which will be different again
from that for editing cells in the central nervous system.
Nonetheless, with the development of multiple different
serotypes of AAV that preferentially transduce different
cell types in vivo [51, 52], the development of new
methods of delivering mRNAs to cells, and the increas-
ing sophistication of nanoparticles (both lipid and nonli-
pid based) to deliver to specific tissues, there are likely
to be solutions forthcoming soon. Developing a delivery
method in which the nuclease is not expressed for a sus-
tained period of time is important both from a genotoxic
standpoint and from an immunologic standpoint. It
should be anticipated, until proven otherwise, that all of
the engineered nuclease platforms will be seen by the
immune system as foreign and will elicit a robust im-
mune response that will both eliminate the therapeutic-
ally edited cells and perhaps cause toxic organ damage.
As therapeutic genome editing gathers momentum, an
increasing number of innovative approaches are being
developed. These can be classified along three different
axes: NHEJ- vs. HR-mediated genome editing; ex vivo vs.
in vivo delivery; and suitability for genetic vs. infectious vs.
nongenetic diseases. Examples of some of these various
strategies are discussed below.
Potential therapeutic applications of
nonhomologous end-joining mediated genome
editing
Diseases that can be addressed using NHEJ-mediated gen-
ome editing are those in which mutating a genetic element,
whether a coding region, a regulatory element, or some
other genetic element, might result in clinical benefit. One
example of this approach is to delete the erythroid enhan-
cer for Bcl11A in hematopoietic stem/progenitor cells
(HSPCs) in order to upregulate γ-globin to treat sickle celldisease and β-thalassemia [53–55]. Both sickle cell disease
and β-thalassemia are monogenic diseases caused by muta-
tions in the HBB gene. Both diseases could be cured if
HBG, a gene closely related to HBB, could be upregulated
such that it could either replace the missing γ-globin pro-
tein (in β-thalassemia) or counteract the dysfunctional γ-
globin protein (in sickle cell disease). Studies of the globin
switch have demonstrated that Bcl11-A is a transcriptional
repressor of HBG and that repression of Bcl11A results in
the de-repression of HBG [56]. Moreover, when used as a
research tool, genome editing demonstrated that deletion
of a specific regulatory element in the Bcl11A gene, the
erythroid enhancer, could repress Bcl11A in the erythroid
lineage but not in the B-cell lineage, thus validating the in-
activation of this element by NHEJ-mediated genome edit-
ing in HSPCs as a therapeutic strategy [53].
A different strategy using NHEJ-mediated genome edit-
ing is being developed to treat Duchenne’s muscular dys-
trophy, a monogenic disease cause by mutations in the
Dystrophin gene. In this in vivo strategy, a single nuclease
might be delivered into muscle fibers to create an inser-
tion/deletion that compensates for the original frameshift
mutation (thus reverting the pathologic reading frame
mutation). Alternatively, a pair of nucleases might be
delivered into muscle fibers to delete a set of exons in
order to delete pathologic mutations, thereby converting
Duchenne’s muscular dystrophy to the less severe Becker’s
muscular dystrophy. Proof-of-concept studies have been
published for both of these strategies, but the challenge
that remains is to achieve the desired editing in a fraction
of muscle fibers, including the heart and diaphragm tis-
sues, large enough to alter the clinical course of the disease
significantly [57–59]. In addition, as a general principle,
any disease that might be treated by RNA interference
(RNAi)-mediated knockdown of a gene [60, 61] might be
more definitively treated by genome editing. Editing would
provide permanent knockdown of the gene and therefore
would not require repeated dosing of knockdown RNAi
reagent.
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ome editing has already reached Phase II clinical trials
as a method to generate a T-cell population that is re-
sistant to HIV infection. These studies are based on the
discovery that people with bi-allelic mutations in the
CCR5 gene are near completely resistant to HIV infec-
tion, and on the cure of an HIV patient by allo-HSCT
using a donor whose stem cells contained a bi-allelic
mutation in the CCR5 gene [62]. Sangamo Biosciences
and their collaborators have engineered ZFNs to target
the CCR5 gene, and then used these ZFNs to mutate the
CCR5 gene in primary T cells derived from patients
already infected with HIV [63–65]. In Phase I trials, they
demonstrated that this approach was both feasible and
safe, and Phase II trials are now underway [65].
In vivo NHEJ-based genome-editing approaches are
also being developed for infectious diseases. In multiple
proof-of-concept studies, nucleases have been engineered
to recognize key elements of viral genomes (including
those of HIV and hepatitis B) in order to create mutations
that will inactivate the virus [66–68]. These studies have
demonstrated that such nucleases can be engineered and
that they can alter viral kinetics in in-vitro models, but
real challenges remain in how to apply this strategy in an
in vivo setting where delivery to nearly all infected cells
must be achieved and in a way that does not require con-
stitutive expression of the nuclease.
Finally, NHEJ-mediated genome editing has been ap-
plied in a proof-of-concept study as a potential approach
to treat high cholesterol. PCSK9 is a regulator of choles-
terol and those who have the rare homozygous deficiency
in PCSK9 are otherwise healthy but have extremely low
cholesterol levels. In vivo nuclease-mediated genome edit-
ing has been used to mutate the PCSK9 gene in livers,
with a resultant drop in cholesterol levels [69, 70]. Al-
though there are multiple caveats to these experiments,
they do show, in principle, how in vivo editing might be
used to treat multifactorial diseases whose course could
be modified by using genome editing to create a clinically
useful genotype.
Potential therapeutic applications of homologous
recombination mediated genome editing
Deep understanding of the pathophysiology of certain
diseases can show how NHEJ-mediated genome editing
could be used as therapy for those diseases. In general,
however, the ability to harness HR-mediated genome
editing both ex vivo and in vivo has the potential to im-
pact on an even larger number of diseases.
There are numerous genetic diseases of HSPCs, such
as sickle cell disease, β-thalassemia, severe combined im-
munodeficiency and chronic granulomatous disease, that
can be cured by allo-HSCT. In allo-HSCT for these
types, the hematopoietic system is replaced by cellscontaining at least one wild-type version of the gene
and, for this reason, some have called it ‘allogeneic gene
therapy’ [71]. Using HR-mediated genome editing, it
would be possible to replace genetically correct allogen-
eic stem cells with genetically corrected autologous cells.
This can be done either by directly correcting the defect-
ive gene [46] or by using HR-mediated genome editing
to target the therapeutic transgene to a ‘safe harbor’
[72]—a genomic site in which the transgene would be
expressed at the needed levels without causing dysfunc-
tion or transformation of the modified cell [73]. One po-
tential issue with gene correction by HR is that many
genetic diseases, sickle cell disease being an exception, are
caused by mutations throughout the gene. The engineered
nuclease toolbox is now such that one might consider de-
signing nucleases for each individual mutation. An alter-
native approach, however, is to design the donor vector
such that, after HR, the integrated transgene would func-
tionally correct all (or most) of the disease-causing
mutations [74, 75]. Using this strategy, a single set of
reagents could be developed to treat all individuals
with the genetic disease—a strategy that would signifi-
cantly simplify the development and regulatory
process.
Proof-of-concept studies for in vivo HR-mediated gen-
ome editing have been described in which either the
underlying mutant gene was directly corrected or a
transgene was integrated into a specific location such
that it would be expressed at sufficient levels to rescue
the underlying defect [76]. In the direct gene correction
strategy, nucleases and donor vectors were delivered to
fumarylacetoacetate hydrolase (FAH)-deficient mice.
Normally, FAH deficiency causes hepatocyte death but,
after delivery of the genome-editing machinery, a small
number of hepatocytes were corrected. These corrected
hepatocytes then re-populated the remaining liver and
rescued the mouse from liver failure. In these experi-
ments, the corrected cells had a tremendous selective
advantage over uncorrected cells, and the principle of
selective advantage is one that is regularly used by the
gene therapy community. In the transgene-targeting
strategy, nucleases were used to stimulate the targeted
introduction of a therapeutic transgene (either Factor IX
or lysosomal storage enzymes) into a locus that drove
high levels of expression from hepatocytes [77–79]. In
this way, a small number of modified hepatocytes were
able to rescue an underlying genetic defect at a systemic
level.
Ex vivo HR-mediated genome editing is also being de-
veloped as a method to create an HIV-resistant immune
system [20]. One of the hallmarks of HIV is its ability to
mutate and escape any inhibition, and thus it is possible
that simply mutating the CCR5 co-receptor will not be
sufficient to confer cellular resistance to HIV. Moreover,
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that enter cells through the CXCR4 coreceptor and thus
would escape any approach that only targets CCR5; but
using HR-mediated editing, one can simultaneously in-
activate CCR5 while inserting a cassette of antiHIV
genes, thereby creating multiple genetic blocks to the
HIV lifecycle and inhibiting variants that enter through
the CXCR4 co-receptor.
Finally, ex vivo HR-mediated genome editing has been
shown in proof-of-concept experiments to be therapeutic
for an acquired disease. In these experiments, fibroblasts
were engineered by HR to secrete a wound-healing
growth factor [80]. When these engineered fibroblasts
were implanted into mouse wounds, they hastened wound
healing by stimulating vascularization. In principle, this
demonstrates that cells can be engineered to secrete thera-
peutic proteins that rescue nongenetic diseases. This
might be applied to wound healing in humans but one
can also speculate, for example, that a similar approach
might be used to engineer cells, either ex vivo or in vivo,
to secrete neuroprotective factors to slow or halt neurode-
generation or to facilitate neurogenesis or nerve regener-
ation after trauma.
Safety and toxicology
One of the tremendous potential advantages of genome
editing, when compared to other methods of perman-
ently altering the genome of cells, is the specificity of the
process. Nevertheless, the induction of a DSB through a
site-specific engineered nuclease is a critical aspect of
gene editing and it is well known that DSBs can generate
genomic instability, including chromosomal transloca-
tions, chromosome loss and aneuploidy [81]. Thus, a key
aspect in the clinical development of nuclease-mediated
genome editing is to establish a series of assays that as-
sess the potential safety of the process. Unfortunately,
the field is too young for there to be any single assay or
set of assays that has been validated as establishing
whether an editing process will be safe in humans [82].
Instead, safety and toxicology analysis is assessed ac-
cording to the following principles: 1) minimizing or
eliminating off-target DSBs and the consequent inser-
tions/deletions that may be generated; 2) assessing the
functional behavior of edited cells using the best avail-
able models; and 3) putting the process of genome edit-
ing in the context of the natural genomic instability
that occurs continuously in everybody. These funda-
mental criteria apply to whichever nuclease platform is
utilized because each platform works through the cre-
ation of a DSB.
There are biased and unbiased approaches to assessing
the specificity of a nuclease [83, 84]. Bioinformatic tools
that are based on searching for sites that have sequences
similar to the intended target site can help to predictwhich off-target sites should be examined. Once a set of
sites is identified, deep sequencing can be used to inter-
rogate those sites to determine whether there are
nuclease-generated insertions/deletions at those sites.
Given the current error rate of deep sequencing meth-
odologies, the limit of detection for a given site is
~0.01 % (or in 1 in 10,000). Moreover, the bioinformatics
algorithms are still in their early development and still
do not reliably identify all potential off-target sites. To
complement the biased approach using bioinformatics,
there are newly developed unbiased tools, including
break Guide-seq [85], HTGTS [86], BLESS [70], and
Digenome-seq [87]. Other assays use extrachromosomal
DNA, including AAV [88], naked DNA plasmids [19],
and integration-defective lentiviral vectors [89], to cap-
ture breaks and to help assess the specificity of a nucle-
ase. These tools have particular power because they
can also identify gross chromosomal rearrangements
(like translocations) that are not identified using biased
approaches. As chromosomal translocations will be a
rare but inevitable consequence of induced DSBs, it
would be prudent to avoid targeting genes that are in-
volved in cancer-associated chromosomal transloca-
tions at this stage in the development of therapeutic
genome editing.
The challenge with these unbiased approaches is that
they have been developed in specialized cancer cell lines,
which do not have intact DNA-repair pathways, and
they need to be adapted to primary clinically relevant
cell types with intact DNA repair pathways. Nonetheless,
these tools still provide useful information in optimizing
the specificity of a nuclease. For example, if these assays
reveal that the nuclease has multiple off-target sites,
then they suggest that the nuclease should be redesigned
to be more specific. For ZFNs, this might entail using
the obligate heterodimer structure for the nuclease do-
main or exploring specific alterations in the amino acids
that mediate recognition of the target sequence [90]. For
TALENs, this might entail using the obligate heterodi-
mer structure for the nuclease domain or using alterna-
tive repeat variable di-residues (RVDs) for the TAL
effector recognition domain [91]. For CRISPR/Cas9 nu-
cleases, improved design might entail testing a different
guide sequence, or using a truncated guide sequence
[92] or a paired-nickase approach [93, 94]. For all of the
platforms, specificity is increased by limiting the dur-
ation of expression of the nuclease, the pharmacologic
equivalent of decreasing the AUC (‘area under the
curve’) of nuclease exposure [39, 95, 96].
An approach that complements attempts to identify
the potential off-target sites of the nuclease directly is to
evaluate the genome-editing process by a more classical
functional pharmacology–toxicology approach. This
strategy evaluates whether the genome-editing process
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function (for example, the ability of hematopoietic stem
cells to reconstitute multilineage hematopoiesis), that
transform into cancer cells, or that cause the population
to become clonally skewed (a possible harbinger of the
creation of cells that might transform over a time frame
beyond that which can be measured using current as-
says) [82].
The biased, unbiased, and functional approaches need
to be performed in the therapeutic cell type of interest
using the clinical-grade genome-editing process planned
because assessment in other cell types, particularly already-
transformed cancer cell lines, may not be relevant.
An important principle to keep in mind is that dividing
cells are undergoing genomic challenge continuously.
It is estimated that every time a cell divides, it must re-
pair 20–40 DNA DSBs, not to mention millions of
other types of DNA lesions [97, 98]. The consequence
of this natural genomic challenge is that a normal div-
iding stem cell acquires ~3–30 mutations for each cell
division; it is estimated 1 million mutations occur
every second in an individual. It has been suggested
that gene correction by genome editing of patient-
derived induced pluripotent cells, followed by whole-
genome sequencing to determine if deleterious mutations
have occurred, might be a safer approach. The mutational
burden caused by ex vivo expansion from a single cell to a
therapeutically relevant cell number (for hematopoietic
diseases this is in the order of 50–800 million cells de-
pending on the size of the patient) may, in reality, be more
oncogenic than just modifying a large number of somatic
cells without being able to sequence the genome of any
one cell.
Challenges of germline genome editing
The development of a powerful genome-editing toolbox,
combined with the use of this toolbox to create a wide
variety of genetically modified species by zygote injection
[16], has raised the possibility that someone might use
genome editing in human zygotes to create human be-
ings [99, 100]. This possibility was further highlighted by
researchers in China who used the approach in tripro-
nuclear human zygotes (human zygotes that are genetic-
ally incapable of developing into a human but are nearly
identical in concept to diploid zygotes) [101]. The tripro-
nuclear zygote injection experiments highlighted the in-
efficiency and unpredictability of the process—findings
that would have been predicted by animal experiments
using healthy diploid zygotes. These results clearly dem-
onstrate that genome-editing technology applied as zyg-
ote injection, even if judged ethically permissible or
desirable, is not ready for human application. Nonethe-
less, these specific experiments and the general concept
have generated a large number of headlines in bothhigh-profile journals and the lay press. Which direction
the conversation turns remains to be determined, but
there are several principles that I hope remain at the
forefront. First, the ethical issue should not impede the
use of powerful genome-editing tools in research to pro-
vide a better understanding of germ cells, germ cell de-
velopment, and early embryonic development. Second,
the discussion should be led by thought leaders from a
variety of different fields and should include voices from
a broad range of stakeholders, including those families
who lives have been impacted over multiple generations
by the transmission of devastating genetic diseases
through their family tree. Third, there is no single ethical
viewpoint that has predominance and an ongoing, itera-
tive process in which new understandings and view-
points can be incorporated is the desired outcome rather
than a defined resolution at a single point in time. Fi-
nally, the issue of using genome editing that might re-
sult in the transmission of specific genotypes to future
generations needs to be put into the context of activities
already taking place that similarly affect the genotypic
makeup of future generations. Two such examples are
pre-implantation genetic diagnosis with selective zygote
implantation and curing or helping patients with genetic
diseases (an unequivocally good thing) such that they
might not pass down their disease-causing mutation to
their children.
Future perspectives
The precision of genome editing and the ability to cor-
rect disease-causing typographical errors in the DNA
sequence have always made the field conceptually ap-
pealing. All of the strategies of genome editing could be
achieved using engineered meganucleases and ZFNs,
but the challenge of making highly active and specific
versions of these tools has limited the number of inves-
tigators who were committed to the concept. With the
development of TALENs and then CRISPR/Cas9 nucle-
ases, the barrier to entry for investigators was decreased
so dramatically that essentially any researcher who is
interested can begin to explore their own innovative
ideas. With this explosion in interest, the pace of pro-
gress has increased exponentially. In the decade since
the first use of ZFNs in human cells there has been just
one clinical trial, so it is exciting to predict that in the
next decade there will be tens (if not more) of genome
editing-based clinical trials that will be developed by ac-
ademics, biotechnology start-ups and pharmaceutical
companies.
Nonetheless, there remain important issues to be re-
solved. These include developing a regulatory frame-
work that is tailored to the underlying technology
rather than one that is based on a different therapeutic
foundation (such as small molecules or antibody
Porteus Genome Biology  (2015) 16:286 Page 10 of 12biologics). There is also a need to develop safe and ef-
fective mechanisms to deliver the genome-editing ma-
chinery to a wide variety of tissues in vivo, including
the liver, eye, muscle, heart, and brain. Finally, a flex-
ible and adaptive regulatory framework needs to be
developed to take into account the ethical and scien-
tific issues around the potential use of genome editing
that might alter the genetics of future generations (‘al-
tering heredity’). This framework needs to take into
account the diverse group of stakeholders who are af-
fected by the issue and must respect culturally differ-
ent perspectives.
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